Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

Orphan Drug Development in Personalized Medicine

Session Chair(s)

Philip (P.J.)  Brooks, PhD

Philip (P.J.) Brooks, PhD

Deputy Director, Division of Rare Diseases Research Innovation

National Center for Advancing Translational Sciences (NCATS), NIH, United States

For many years, drug development in oncology focused on treatments for tumors in specific parts of the body. However , with the advent of genomic sequencing, it has become clear that anatomically different tumors can have the same mutation that result in susceptibility to a drug, and that it is those mutations, rather than the anatomical site of the tumor, that should drive patient selection in clinical trials. This same approach, grouping patients based on molecular targets rather than clinical phenotypes, has broader implications for orphan drug development beyond oncology. In this session, the speakers will cover a variety of topics related to this issue, including rare mutation oncology trials, innovative study designs, and perspectives on orphan drug development in the age of personalized medicine.

Learning Objective : Discuss insights for overcoming barriers to successful precision medicine development in rare mutation oncology trials; Describe different types of study designs for orphan drug development in personalized medicine; Identify different perspectives on orphan drug development in the age of personalized medicine.

Speaker(s)

Angela  Qu, MD, PhD

Rare Mutation Oncology Trials: Learnings Over Barriers and Enablers for Successful Precision Medicine Development

Angela Qu, MD, PhD

Parexel, United States

Vice President, Translational Medicine

Richard  Huckle, MSc

Innovative Study Designs for Better Outcomes

Richard Huckle, MSc

Osiris Pharma, United Kingdom

Regulatory and Development Consultant

Philip (P.J.)  Brooks, PhD

Adapting the Oncology Basket Trial Model to Rare Diseases: Grouping Patients by Underlying Etiology Rather Than Clinical Characteristics to Accelerate Clinical Trials

Philip (P.J.) Brooks, PhD

National Center for Advancing Translational Sciences (NCATS), NIH, United States

Deputy Director, Division of Rare Diseases Research Innovation

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.